多西环素治疗阿奇霉素耐药的支原体肺炎患儿的临床疗效及对血液流变学指标、炎症及心肌损伤的影响  

Clinical Efficacy of Doxycycline in the Treatment of Azithromycin-Resistant Children with Mycoplasma Pneumonia and its Effect on Hemorheological Indices,Inflammation and Myocardial Damage

作　　者：张淑华 延新新 翟德菊[1] ZHANG Shu-hua;YAN Xin-xin;ZHAI De-ju(Department of Paediatrics,Zhengzhou Third People's Hospital,Zhengzhou,Henan,450053,China;Department of Paediatrics,Qilu Hospital of Shandong University Dezhou Hospital,Dezhou,Shandong,253000,China)

机构地区：[1]郑州市第三人民医院儿科,河南郑州450053 [2]山东大学齐鲁医院德州医院儿科,山东德州253000

出　　处：《中国血液流变学杂志》2024年第4期612-616,共5页Chinese Journal of Hemorheology

摘　　要：目的探究多西环素治疗阿奇霉素耐药的支原体肺炎患儿的临床疗效及对血液流变学指标、炎症因子的影响。方法收集2023年7月—2024年7月郑州市第三人民医院和山东大学齐鲁医院德州医院收治的支原体肺炎患儿相关病历资料进行回顾性分析,100例支原体肺炎患儿存在阿奇霉素耐药,根据是否应用多西环素治疗分为多西环素组(n=50)和阿奇霉素组(n=50)。比较两组患儿的临床疗效,并比较两组患儿的血液流变学指标和炎症因子水平的差异。结果治疗前两组患儿的肺功能、血液炎症因子及血液流变学指标差异均无统计学意义(P>0.05)。治疗后,两组患儿的肺功能(PEF、FEV1、FEV1/FVC)均显著改善,但多西环素组改善更为显著(P<0.05);临床疗效上,多西环素组的总体有效率也显著高于阿奇霉素组(P<0.05)。此外,多西环素组在降低IL-6、减轻心肌损伤及改善血液流变学指标(HCT、ESR、FIB)方面均优于阿奇霉素组(P<0.05)。结论多西环素治疗阿奇霉素耐药的支原体肺炎患儿具有良好的临床疗效,能够有效改善患儿肺功能,提高免疫力,恢复血液流变学指标并降低炎症水平及心肌损伤。Objective To explore the clinical efficacy of Doxycycline in the treatment of Azithromycin resistant Mycoplasma pneumonia in children and its effects on hemorheological indexes and inflammatory factors.Methods The medical records of children with Mycoplasma pneumonia admitted to Zhengzhou Third People's Hospital and Qilu Hospital of Shandong University Dezhou Hospital from July 2023 to July 2024 were collected and analyzed retrospectively.100 children with Mycoplasma pneumonia were resistant to Azithromycin.According to whether they were treated with Doxycycline or not,they were divided into Doxycycline group(n=50)and Azithromycin group(n=50).The clinical efficacy of the two groups were compared,and the differences of hemorheological indexes and inflammatory factors between the two groups were compared.Results There was no significant difference in pulmonary function,blood inflammatory factors and hemorheological parameters between the two groups before treatment(P>0.05).After treatment,the pulmonary function(PEF,FEV1,FEV1/FVC)of the two groups were significantly improved,but the improvement of Doxycycline group was more significant(P<0.05).In terms of clinical efficacy,the overall effective rate of Doxycycline group was also significantly higher than that of Azithromycin group(P<0.05).In addition,Doxycycline group was superior to Azithromycin group in reducing IL-6,alleviating myocardial injury and improving hemorheological indexes(HCT,ESR,FIB)(P<0.05).Conclusion Doxycycline has good clinical efficacy in the treatment of Azithromycin-resistant Mycoplasma pneumonia,which can effectively improve the lung function of children,improve immunity,restore the blood rheological indexes and reduce the level of inflammation and myocardial damage.

关 键 词：多西环素 阿奇霉素耐药 支原体肺炎 血液流变学指标 炎症因子 心肌损伤 

分 类 号：R725.6[医药卫生—儿科]